Department of Medicine, University of British Columbia, Vancouver, British Columbia.
Can Respir J. 2011 Sep-Oct;18(5):262-4. doi: 10.1155/2011/713821.
Adalimumab is a human monoclonal antibody against tumour necrosis factor-alpha that has been associated with acute lung toxicity, mainly in patients with rheumatoid arthritis. Descriptions of similar patterns of lung injury in patients treated with adalimumab for inflammatory bowel disease are emerging in the literature. A case involving a 45-year-old man with Crohn's disease who developed a nonbronchiolitis inflammatory nodular pattern of lung injury after starting adalimumab is reported.
阿达木单抗是一种针对肿瘤坏死因子-α的人源单克隆抗体，与急性肺毒性相关，主要发生在类风湿关节炎患者中。文献中也出现了一些接受阿达木单抗治疗炎症性肠病的患者出现类似的肺损伤模式的病例。本文报告了一例 45 岁克罗恩病男性患者，在开始使用阿达木单抗后出现非细支气管炎性炎性结节样肺损伤。
